We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Don't Revive Restasis Patents, Generic Cos. Urge Fed. Circ.

Law360 (March 8, 2018, 4:02 PM EST) -- A Texas federal judge rightly invalidated claims from four patents covering Allergan’s dry-eye medicine Restasis, as they directly copied earlier patents the drugmaker had filed, a trio of generic-drug makers told the Federal Circuit in a brief unsealed Wednesday.

While Allergan Inc. claims the newest patents stem from “unexpected results” at trials, Teva Pharmaceuticals USA Inc., Mylan Pharmaceuticals Inc. and Akorn Inc. say those results were directly outlined in earlier trials. The patented formulation, which relates to the efficacy of different doses of Restasis, works exactly...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.